Many pharmaceutical companies have exited the antibiotic R&D market in the past few decades and focused instead on more profitable therapeutic areas such as drugs for cancer (sold at high prices) or chronic diseases (taken by individuals for life). Incentives to sustain the R&D of new treatments for bacterial infections take the form of ‘push’ funding and ‘pull’ funding. Some countries have instituted a ‘pull’ funding mechanism, the so called ‘Netflix’ subscription models, and numerous governments and philanthropic foundations provide ‘push’ funding for translational research through funders such as CARB-X.

This webinar discussed potential solutions, including support for non-profit R&D organizations, to get new treatments to patients in the scenario of inadequate investment in industry R&D i.e., few or no additional ‘pull’ investments, or ‘pull incentives’ that do not meet industry expectations as to the size of the reward.

It examined the benefits and drawbacks of other solutions to pay for antibiotic R&D, how governments can collaborate to sustain such approaches, and the role of these potential solutions in the long term.

This webinar was aimed at politicians, policy makers and funders.


  • Radha Rangarajan, Director, CSIR-Central Drug Research Institute, Lucknow (India)
  • Aaron S. Kesselheim, Professor of Medicine, Brigham and Women’s Hospital/Harvard Medical School (USA)
  • Henry Skinner, Chief Executive Officer, AMR Action Fund (USA)


  • Laura Jung, Medical doctor & AMR researcher, Leipzig University Medical Center, Division of Infectious Diseases and Tropical Medicine, Leipzig (Germany)

This webinar including an interactive Q&A session was broadcast on 27 February 2024.

If you have questions or comments, please let us know: